Clinical trial
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
NCT00023855 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00023855 |
|---|---|
| Title | PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I and Pharmacodynamic Study of Proteasome Inhibitor, PS-341, in Combination With Doxorubicin in Patients With Advanced Solid Tumors |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bortezomib, doxorubicin hydrochloride |
| Start date | Jun 1, 2001 |
| Primary completion | Oct 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: